Aurobindo Pharma subsidiary Auro Pharma is acquiring the non-oncology prescription formulations business of Khandelwal Laboratories in a slump sale for a cash consideration of ₹325 crore, subject to working capital true-up adjustments under the definitive agreements, Aurobindo said in a filing on Thursday.
The business comprises 23 brands marketed across 67 SKUs and nine pipeline products, with anti-infective and pain management as its major portfolios.
It reported turnover of ₹113.5 crore in 2024-25 and an EBITDA of ₹28.9 crore. The operation includes a field force of about 470 people and more than 1,600 stockists and related distribution infrastructure.
The transaction, effective January 1, 2026, will add brands in pain management and anti-infective, complement Aurobindo’s existing product portfolio and support expansion in the domestic market.
Leave a Reply